|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2005-5-25
|
|
pubmed:abstractText |
Recurrent extremity soft tissue sarcoma (STS) in a previously operated and irradiated area can usually be managed only by amputation. Tumor necrosis factor (TNF)-alpha-based isolated limb perfusion (ILP) is an established alternative to achieve limb salvage but is assumed to require sufficient vasculature. Because radiotherapy is known to destroy vasculature, we wanted to evaluate retrospectively whether the outcome of ILP in patients with radiotherapy for their primary tumor nonetheless showed a benefit from TNF treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1068-9265
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
406-11
|
|
pubmed:dateRevised |
2007-7-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15915375-Adult,
pubmed-meshheading:15915375-Aged,
pubmed-meshheading:15915375-Aged, 80 and over,
pubmed-meshheading:15915375-Antineoplastic Agents, Alkylating,
pubmed-meshheading:15915375-Arm,
pubmed-meshheading:15915375-Chemotherapy, Cancer, Regional Perfusion,
pubmed-meshheading:15915375-Combined Modality Therapy,
pubmed-meshheading:15915375-Female,
pubmed-meshheading:15915375-Humans,
pubmed-meshheading:15915375-Leg,
pubmed-meshheading:15915375-Limb Salvage,
pubmed-meshheading:15915375-Male,
pubmed-meshheading:15915375-Melphalan,
pubmed-meshheading:15915375-Middle Aged,
pubmed-meshheading:15915375-Neoplasm Recurrence, Local,
pubmed-meshheading:15915375-Sarcoma,
pubmed-meshheading:15915375-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs.
|
|
pubmed:affiliation |
Department of Surgical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE Rotterdam, The Netherlands.
|
|
pubmed:publicationType |
Journal Article
|
